Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 First-in-Human Study of ABBV-324 in Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer
jRCT2031250590Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2025
01
Overview
Phase 1, open-label, single-arm trial of ABBV-324 in hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events, Number of Participants with Change in Vital Signs and 3 more. Started Jun 2025; status: recruiting.
02
Drugs
ABBV-324
03
Conditions
hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031250590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250590.